Qualigen Therapeutics IncNASDAQ:QLGNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE4.4900
- TODAY'S CHANGE (%)0.0700 (1.5837%)
- Bid / Lots4.4100/ 5
- Ask / Lots4.5000/ 2
- Open / Previous Close4.4500 / 4.4200
- Day Range
- 52 Week Range
- Volume47,154
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QLGN |
|---|---|---|
| 09:32 ET | 828 | 4.45 |
| 09:37 ET | 2112 | 4.4 |
| 09:48 ET | 539 | 4.41 |
| 09:50 ET | 100 | 4.49 |
| 09:51 ET | 4500 | 4.4899 |
| 09:57 ET | 2800 | 4.49 |
| 10:00 ET | 500 | 4.61 |
| 10:02 ET | 166 | 4.58 |
| 10:04 ET | 458 | 4.5722 |
| 10:06 ET | 4581 | 4.56 |
| 10:08 ET | 1999 | 4.5792 |
| 10:13 ET | 3700 | 4.5002 |
| 10:15 ET | 100 | 4.56 |
| 10:26 ET | 100 | 4.56 |
| 10:29 ET | 100 | 4.51 |
| 10:36 ET | 200 | 4.51 |
| 10:44 ET | 500 | 4.5128 |
| 10:45 ET | 100 | 4.57 |
| 10:51 ET | 300 | 4.56 |
| 10:54 ET | 1000 | 4.53 |
| 10:56 ET | 10888 | 4.54 |
| 11:12 ET | 100 | 4.4293 |
| 11:30 ET | 100 | 4.49 |
| 11:41 ET | 100 | 4.47 |
| 11:56 ET | 100 | 4.46 |
| 11:59 ET | 2500 | 4.45 |
| 12:08 ET | 100 | 4.48 |
| 12:24 ET | 100 | 4.4528 |
| 12:46 ET | 1700 | 4.47 |
| 01:02 ET | 100 | 4.48 |
| 01:04 ET | 100 | 4.48 |
| 01:13 ET | 300 | 4.45 |
| 01:31 ET | 100 | 4.48 |
| 01:45 ET | 100 | 4.48 |
| 01:49 ET | 335 | 4.49 |
Nov 19, 2024
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares, from 9:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
9:00AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 13, 2024
*DJ Qualigen Therapeutics Names Graydon Bensler to Board, from 5:38PM ET on Wednesday Nov 13, 2024 by Dow Jones
5:38PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 1, 2024
Shares Expected to Begin Trading on Split-Adjusted Basis onNovember 5, 2024, from 9:00AM ET on Friday Nov 01, 2024 by Dow Jones
9:00AM ET on Friday Nov 01, 2024 by Dow Jones
Oct 24, 2024
*DJ Qualigen Therapeutics Offering Up to 14M Shrs, from 5:27PM ET on Thursday Oct 24, 2024 by Dow Jones
5:27PM ET on Thursday Oct 24, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Qualigen Therapeutics Inc | 3.3M | -0.1x | --- |
Quoin Pharmaceuticals Ltd | 3.1M | -0.1x | --- |
Enveric Biosciences Inc | 3.4M | -0.1x | --- |
Bio Path Holdings Inc | 3.4M | -0.1x | --- |
Lixte Biotechnology Holdings Inc | 3.4M | -0.9x | --- |
Actavia Life Sciences Inc | 3.1M | -7.5x | --- |
Company Information
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Contact Information
- Headquarters
- 1880 Century Park E Ste 1000LOS ANGELES, CA, United States 90067-1623
- Phone
- 310-203-1000
- Fax
- 310-919-1600
Executives
- President, Director
- Campbell Becher
- Interim Chief Executive Officer and Interim Chief Financial Officer, Director
- Kevin Richardson
- Independent Director
- Braeden Lichti
- Independent Director
- Robert Lim
- Independent Director
- Cody Price
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 736.4K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.72 |
EPS | $-55.62 |
Book Value | $-19.62 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
